<DOC>
	<DOC>NCT02802644</DOC>
	<brief_summary>This study evaluate the effect of dipeptidyl-peptidase 4 inhibitor on vascular healing after biodegradable polymer based sirolimus eluting stent implantation in diabetic pateints.</brief_summary>
	<brief_title>The Effect of DPP4 Inhibitor on Vasclular Healing</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>NonST segement elevation acute coronary syndrome Left main disease Known hypersensitivity or contraindication to any of the following medications: Heparin, aspirin, clopidogrel, sirolimus, siptagliptin and statin Congestive heart failure (patients with LVEF &lt;30% or cardiogenic shock) Uncontrolled myocardial ischemia (repeated chest pain or dyspnea after revascularization) Uncontrolled ventricular arrhythmia History of malignancy with chemotherapy Serious hematologic disease (e.g. CML, MDS) Current infectious disease needs antibiotics therapy Creatinine level &gt;1.5 mg/dL or dependence on dialysis Other severe concurrent illness (e.g. active infection, malignancy). Life expectancy of less than one year Pregnancy or women with potential childbearing Type I DM Treatment with insulin History of pancreatitis Who cannot read the informed consent form (e.g. illiteracy, foreigner)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>